Percutaneous radiofrequency ablation of renal tumors: midterm results in 16 patients

PURPOSE: To evaluate the outcome of 16 patients after percutaneous radiofrequency ablation of renal tumors. MATERIALS AND METHODS: Sixteen patients (nine women, seven men; mean age, 61+/-9 years) with 24 unresectable renal tumors (mean volume, 4.3+/-4.3 cm3) underwent CT-guided (n=20) or MR imaging-guided (n=4) percutaneous radiofrequency ablation using an expandable electrode (Starburst XL, RITA Medical Systems, Mountain View, CA) with a 150-W generator. The initial follow-up imaging was performed within 1-30 days after RF ablation, then at 3-6 month intervals using either CT or MRI. Residual tumor volume and coagulation necrosis was assessed, and statistical correlation tests were obtained to determine the strength of the relationship between necrosis volume and number of ablations. RESULTS: Overall, 97 overlapping RF ablations were performed (mean, 3.5+/-1.5 ablations per tumor) during 24 sessions. Five or more RF ablations per tumor created significant larger necrosis volumes than 1-2 (p=.034) or 3-4 ablations (p=.020). A complete ablation was achieved in 20/24 tumors (primary technical success, 83%; mean volume of coagulation necrosis: 10.2+/-7.2 cm3). Three of four residual tumors were retreated and showed complete necrosis thereafter. Three major complications (one percuatneous urinary fistula and two ureteral strictures) were observed after RF ablation. No further clinically relevant complications were observed and renal function remained stable. During a mean follow-up of 11.2 months (range, 0.2-31.5), 15/16 patients (94%) were alive. Only one patient had evidence of local recurrent tumor. CONCLUSION: The midterm results of percutaneous RF ablation for renal tumors are promising and show that RF ablation is well-suited to preserve renal function.     

Invited. Interactive MRI-guided radiofrequency interstitial thermal ablation of abdominal tumors: Clinical trial for evaluation of safety and feasibility

This clinical trial was performed to evaluate the safety and feasibility of interactive MR-guided radiofrequency (RF) interstitial thermal ablation (ITA) performed entirely within the MR imager. RF-ITA was performed on 11 intra-abdominal metastatic tumors during 13 sessions. The RF electrode was placed under MR guidance on a .2-T system using rapid fast imaging with steady state precession (FISP) and true FISP images. A custom 17-gauge electrode was used and was modified in four sessions to allow circulation of iced saline for cooling during ablation. Tissue necrosis monitoring and electrode repositioning were based on rapid T2-weighted and short-inversion-time inversion recovery (STIR) sequences. Morbidity and toxicity were assessed by clinical and imaging criteria. The region of tissue destruction was visible in all 11 tumors treated, as confirmed on subsequent contrast-enhanced images. No significant morbidity was noted, and patient discomfort was minimal. In conclusion, interactive MR-guided RF-ITA is feasible on a clinical .2-T C-arm system with supplemental interventional accessories with only minor patient morbidity. The ability to completely ablate tumors with RF-ITA depends on tumor size and vascularity.     

MR imaging-guided radiofrequency thermal ablation in the porcine brain at 0.2 T

The aim of this study was to test the hypotheses that (a) MR imaging-guided radiofrequency (RF) thermal ablation is safe and feasible in porcine brain using an open C-arm-shaped low-field MR system, and that (b) induced thermal lesion size can be predicted using low-field MR imaging. Magnetic resonance-guided RF ablation was performed in the cerebral frontal lobes of six pigs. An 18-G monopolar RF electrode was inserted into the porcine brain using MR image guidance and RF was then applied for 10 min. After post-procedure imaging (T2-weighted, T1-weighted before and after gadodiamide administration), the pigs were killed and the brains were used for pathologic examination. Successful RF electrode placement was accomplished in all cases without complications; total magnet time ranged from 73 to 189 min. The thermal lesion size varied from 10 to 12 mm perpendicular to the electrode track and was easily visualized on T2-weighted and enhanced T1-weighted images. Enhanced T1-weighted imaging demonstrated the highest brain-to-RF thermal lesion contrast-to-noise ratio with an average of 1.5 ± 1.6. Enhanced T1-weighted imaging never underestimated pathologic lesion diameter with a mean difference of 2.3 ± 1.0 mm and a radiologic/pathologic correlation of 0.69. Magnetic resonance imaging-guided RF thermal ablation is feasible and safe in the porcine brain using an open MR low-field system. Induced thermal lesion size can best be monitored using enhanced T1-weighted images. In the future, RF ablation under low-field MR guidance may offer an alternative treatment option for primary and secondary brain tumors. Received: 7 February 2000 Revised: 18 July 2000 Accepted: 19 July 2000     

Percutaneous MR imaging-guided radiofrequency interstitial thermal ablation of tongue base in porcine models: implications for obstructive sleep apnea syndrome

PURPOSE: To test the feasibility and safety of a percutaneous magnetic resonance (MR) imaging-guided technique for radiofrequency (RF) interstitial thermal ablation of the tongue base and to correlate MR appearance of induced thermal lesions with histopathologic findings in pigs in acute and chronic porcine models. MATERIALS AND METHODS: A 1-cm-tip RF electrode was inserted percutaneously into the tongue in 10 pigs with 0.2-T real-time MR guidance. The RF electrode was advanced up the midline between lingual arteries and stopped short of tongue mucosa. RF interstitial thermal ablation was performed at 90 degrees C +/- 2 and lasted 10 minutes. Postablation images were obtained with a 1.5-T MR imager. Five pigs were sacrificed immediately (acute model), while five were followed up for 1 month (chronic model) before they were sacrificed. MR-compatible fiducial coils were inserted into tongues with MR imaging guidance prior to RF ablation in the chronic group. Tongues were harvested for histopathologic analysis. Mean thermal lesion volume was compared with the Student t test on images obtained immediately, 2 weeks, and 1 month after RF ablation. Interclass correlation coefficients of lesion diameters at gross pathologic analysis and corresponding diameters with each pulse sequence were calculated. RESULTS: Successful MR imaging-guided electrode positioning was achieved in all procedures without intra- or postprocedure complications because there was high vascular conspicuity and tissue contrast. Thermal lesions appeared hypointense with hyperintense surrounding rims with all sequences in both groups. At pathologic analysis, acute lesions appeared as pale necrotic areas surrounded by hyperemic rims, while chronic lesions demonstrated progressive circumferential fibrosis and significant volume shrinkage (P <.01). Thermal lesion diameters measured at gross pathologic analysis best agreed with corresponding diameters measured on short inversion time inversion-recovery images (interclass correlation coefficient = 0.85). CONCLUSION: The results of this investigation demonstrate MR imaging-guided RF interstitial thermal ablation of the tongue base is feasible and safe and illustrate imaging and pathologic phenomena associated with creation and evolution of the induced thermal lesions.     

MR imaging-guided radio-frequency thermal ablation in the pancreas in a porcine model with a modified clinical C-arm system.

PURPOSE: To test the hypotheses that (a) magnetic resonance (MR) imaging-guided radio-frequency (RF) thermal ablation in the pancreas is safe and feasible in a porcine model and (b) induced thermal lesion size can be predicted with MR imaging monitoring. MATERIALS AND METHODS: MR imaging-guided RF ablation was performed in the pancreas of six pigs. A 17-gauge monopolar RF probe was inserted into the pancreas with MR imaging guidance, and RF was applied for 10 minutes. After postprocedural imaging (T2-weighted, short inversion time inversion-recovery [STIR], and T1-weighted imaging before and after intravenous administration of gadodiamide), the pigs were observed for 7 days and follow-up MR images were acquired. The pigs were sacrificed, and pathologic examination was performed. RESULTS: Successful RF probe placement was accomplished in all pigs; the interventional procedure took 46-80 minutes. Thermal lesions were 12-15 mm perpendicular to the probe track and were best seen on STIR and contrast material-enhanced T1-weighted images with a radiologic and/or pathologic mean difference in RF lesion diameter of 1.7 mm +/- 1.0 (SD) and 0.8 mm +/- 1.2, respectively. Diarrhea was the only side effect during the 1-week follow-up; no clinical signs of pancreatitis occurred. CONCLUSION: MR imaging-guided RF thermal ablation in the pancreas is feasible and safe. Induced thermal lesion size can best be monitored with STIR and contrast-enhanced T1-weighted images. In the future, RF ablation may offer an alternative treatment option for pancreatic cancer.     

MR imaging follow-up after percutaneous radiofrequency ablation of renal cell carcinoma: findings in 18 patients during first 6 months

PURPOSE: To prospectively evaluate the magnetic resonance (MR) imaging findings seen within the first 6 months after radiofrequency (RF) thermal ablation of renal cell carcinoma (RCC). MATERIALS AND METHODS: After providing written informed consent, 18 patients (17 men, one woman; mean age, 71.2 years) with RCC underwent MR imaging-guided percutaneous RF thermal ablation, which was performed by using protocols approved by a comprehensive cancer center protocol committee and the institutional review board for human investigation. The study was Health Insurance Portability and Accountability Act compliant. Follow-up unenhanced T2-weighted MR images and unenhanced and gadolinium-enhanced T1-weighted MR images were acquired immediately, 2 weeks, 3 months, and 6 months after ablation. Thermal ablation zone size was analyzed, and contrast-to-noise ratios (CNRs) were calculated from the signal amplitudes of the thermal ablation zone, perirenal fat, and normal renal cortex on the MR images. Statistical analyses were performed by using the paired Student t test. P < .05 was considered to indicate statistical significance. RESULTS: The mean follow-up time was 16.1 months (range, 6.0-41.2 months). The mean sizes of the thermal ablation zones were 6.8, 7.0, 6.1, and 4.7 cm2, respectively, at immediate, 2-week, 3-month, and 6-month follow-up MR imaging examinations. Thermal ablation zones were uniformly hypointense and had a surrounding bright rim on T2-weighted images and were predominantly hyperintense on T1-weighted images. Thin rim enhancement with central hypointensity was noted on the gadolinium-enhanced images. Gadolinium-enhanced T1-weighted and unenhanced T2-weighted MR images showed significantly higher CNRs than unenhanced T1-weighted MR images. Residual tumor was detected after RF thermal ablation in two cases and was best seen on unenhanced T2-weighted and gadolinium-enhanced T1-weighted MR images. CONCLUSION: After initially increasing in size within the first 2 weeks, renal RF thermal ablation zones involuted during the remainder of the MR imaging follow-up period.     

Transhepatic Approach for Percutaneous Computed-Tomography-Guided Radiofrequency Ablation of Renal Cell Carcinoma

We performed percutaneously radiofrequency (RF) ablation of 5 renal cell carcinomas (mean diameter 26 ± 15 mm) with computed-tomography (CT) fluoroscopic guidance using the transhepatic route. The RF electrode was successfully advanced into all tumors. RF ablation caused one minor complication (small asymptomatic perirenal hematoma); no major complications occurred. The follow-up contrast-enhanced CT images showed no local tumor progression of any tumors in a median period of 10 months (range 3–14 months). In conclusion, it seems that this transhepatic approach is safe and can be an alternative method for electrode insertion during RF ablation of selected renal tumors.     

Femur: MR imaging-guided radio-frequency ablation in a porcine model-feasibility study

PURPOSE: To determine the feasibility of magnetic resonance (MR) imaging-guided and -monitored radio-frequency (RF) ablation of bone. MATERIALS AND METHODS: Seven femurs were treated in five pigs with use of a 0.2-T open MR imager. An 11-gauge bone marrow needle was percutaneously inserted into the distal femur metaphysis with MR fluoroscopy (fast imaging with steady-state precession, or FISP, sequences) to introduce an RF electrode into the bone with further image guidance. Thermal ablation was performed for 10 minutes (90 degrees C +/- 2 [mean +/- SD]). MR follow-up was performed immediately after ablation and again at 7 and 14 days after the procedure (with contrast material-enhanced T1-weighted, T2-weighted, and fast short inversion time inversion-recovery, or STIR, sequences). The animals were sacrificed at day 14. The femurs were sliced, decalcified, and stained. Image analysis was performed to measure lesion diameter and contrast-to-noise ratio (CNR) and to evaluate complications. RESULTS: Technical success was obtained in all animals. The lesion diameter perpendicular to the electrode was 15.4 mm +/- 2.7. No significant complications were noted. The thermal lesions displayed low signal intensity with a sharp rim of high signal intensity. T2-weighted images demonstrated the highest CNR and the lowest error in predicting the lesion size immediately after ablation (2.7 mm +/- 1.3). Contrast-enhanced T1-weighted images demonstrated the highest accuracy at day 14 (1.0 mm +/- 1.0). CONCLUSION: RF ablation of bone with MR imaging as the sole imaging modality is feasible and allows monitoring of the ablation.     

MR imaging-guided radio-frequency thermal ablation of the lumbar vertebrae in porcine models

PURPOSE: To test the hypotheses that (a) magnetic resonance (MR) imaging-guided radio-frequency (RF) thermal ablation of the vertebrae is feasible in porcine models, (b) procedure safety depends on the location of ablation within the vertebra, and (c) MR imaging allows accurate monitoring of induced thermal lesion size and shape. MATERIALS AND METHODS: Ten percutaneous MR imaging-guided RF thermal ablations were randomized over various lumbar vertebral levels and locations in seven pigs. Animals were followed up for 2, 7, or 14 days before sacrifice. Thermal lesion size and shape as measured on MR images obtained immediately after ablation and at follow-up were compared with gross pathologic findings. Mean absolute differences between lesion diameters at pathologic examination and MR imaging were evaluated by using a paired t test, as were differences between lesion-to-vertebra contrast-to-noise ratios obtained for each sequence. Clinical and imaging data were correlated with histologic findings. RESULTS: Successful RF electrode placement in the targeted part of the vertebra was achieved in all procedures. Ablations performed away from neural elements were safe to perform. Pedicular ablations resulted in radiculopathy, whereas ablations performed directly over the posterior cortex resulted in paraplegia. Lesion sizes measured on T2-weighted images were closest to those measured at gross pathologic examination (mean absolute difference, 0.72 mm +/- 0.83 [SD]), followed by those measured on contrast material-enhanced T1-weighted (1.27 mm +/- 0.83) and short inversion time inversion-recovery (STIR) (1.5 mm +/- 1.84) images. Size measurements obtained on T2-weighted images were significantly closer to gross pathologic measurements than were those obtained on contrast-enhanced T1-weighted images (P =.013) but were not different from those obtained on STIR (P =.27) images. The contrast-to-noise ratio was significantly higher for contrast-enhanced T1-weighted images than for T2-weighted (P <.001) or STIR (P <.001) images. CONCLUSION: MR imaging-guided RF thermal ablation of the vertebrae is feasible in porcine models, but the safety of the procedure depends on the location of ablation within the vertebra. MR imaging allows accurate monitoring of thermal lesion size and shape.     

Renal tumors: MR imaging-guided percutaneous cryotherapy--initial experience in 23 patients

PURPOSE: To evaluate the initial clinical experience of magnetic resonance (MR) imaging-guided percutaneous cryotherapy of renal tumors. MATERIALS AND METHODS: Twenty-six renal tumors (diameter range, 1.0-4.6 cm; mean, 2.6 cm) in 23 patients were treated with 27 cryoablation procedures by using a protocol approved by the human subjects committee at the authors' institution. The study complied with the Health Insurance Portability and Accountability Act. Written informed consent was obtained from each patient. There were 17 men and six women with an average age of 66 years (range, 43-86 years). Of 26 masses, 24 were renal cell carcinoma, one was a transitional cell carcinoma, and one was an angiomyolipoma. By using a 0.5-T open MR imaging system and general anesthesia in patients, one to five (mean, 2.4) needlelike cryoprobes were placed and lesions were ablated by using real-time MR imaging for intraprocedural monitoring of ice balls. Tumors were considered successfully ablated if they demonstrated no contrast enhancement at follow-up computed tomography or MR imaging (mean, 14 months; range, 4-30 months). RESULTS: Twenty-four of 26 tumors were successfully ablated, 23 of which required only one treatment session. Two complications occurred in a total of 27 cryoablations: one hemorrhage, which required a blood transfusion, and one abscess, which was treated successfully with percutaneous catheter drainage. CONCLUSION: MR imaging-guided percutaneous cryotherapy of renal tumors shows promise for the treatment of selected small renal tumors, and MR imaging can be used to monitor the treatment intraprocedurally. This technique may prove useful for ablation of renal tumors completely in one session, but long-term follow-up is needed.     

Immediate renal tumor involution after radiofrequency thermal ablation

PURPOSE: To retrospectively evaluate solid renal tumor sizes before and after treatment with radiofrequency (RF) thermal ablation to assess for immediate changes on cross-sectional imaging. MATERIALS AND METHODS: Medical records were retrospectively reviewed in consecutive patients who underwent percutaneous image-guided RF thermal ablation for solid renal tumors between December 12, 2000, and December 13, 2006. All patients underwent noncontrast computed tomography (CT) immediately before and after RF ablation. Maximum renal tumor diameters were measured before and after ablation. Statistical analysis of tumor sizes before and after ablation and change in tumor sizes was performed with the paired Student t test with confidence intervals calculated. RESULTS: Seventy-two renal tumors were treated with RF ablation in 66 patients (42 men, 24 women; mean age, 68.4 years; range, 25-88 y). Mean tumor sizes were 27.5 mm (range, 9.8-64.8 mm; 95% CI, 24.9-30.1 mm) before ablation and 22.1 mm (range, 5.3-67.3 mm; 95% CI, 19.4-24.8 mm) immediately after ablation. An average decrease in renal tumor size of 21% (range, -10% to 50%) was identified, with a mean tumor diameter decrease of 5.4 mm (P < .05; 95% CI, 4.4-6.4 mm). No relationship between size or location of tumors and percentage decrease in size after RF ablation was identified. Measurement of tumors on 1-month follow-up CT showed no appreciable change compared with immediate postprocedural measurements. CONCLUSIONS: Renal tumors decrease in size immediately after treatment with RF thermal ablation. Immediate tumor involution after RF ablation should be anticipated and follow-up imaging studies should ideally be compared to a baseline tumor size measured as soon as possible after ablation.     

Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up

PURPOSE: To describe the appearance of hepatic tumors treated with radio-frequency (RF) ablation on computed tomographic (CT) and magnetic resonance (MR) images and the pattern of residual tumor at the site of RF ablation and to assess prospectively the sensitivity, specificity, and positive and negative predictive CT and MR imaging values in the evaluation of RF treatment. MATERIALS AND METHODS: Thirty-one patients with 50 tumors (nine hepatocellular carcinomas and 41 metastases) treated with RF ablation underwent CT and MR imaging on the same day at 2, 4, and 6 months; CT was performed every 3 months thereafter. CT and MR findings were interpreted separately and prospectively by two reviewers with consensus. For both imaging techniques, appearance of the treated area, treatment efficacy, and complications were assessed at each time. Sensitivity and specificity were determined by using the McNemar test. RESULTS: After a mean follow-up of 19 months, nine tumors showed local regrowth. At 2 months, MR imaging depicted more local regrowths (eight of nine; sensitivity, 89%) than did CT (four of nine; sensitivity, 44%) but without significant differences (P =.12). In two cases, only T2-weighted imaging depicted local regrowth. All nine lesions became conspicuous at 4-month follow-up with both techniques. At 2 months, thin peripheral rim enhancement and arterioportal shunting were found in 24% and 12%, respectively, of the treated tumors. These findings disappeared thereafter and are not linked to tumor regrowth. CONCLUSION: Despite the small number of patients, CT and MR imaging may depicted all local regrowth at 4 months or sooner. MR imaging may have an edge over CT in the early detection of local regrowth.     

Open radio-frequency thermal ablation of renal VX2 tumors in a rabbit model using a cooled-tip electrode: feasibility,safety, and effectiveness

The purpose of this study was to evaluate the feasibility, safety, and effectiveness of radio-frequency (RF) ablation using an internally cooled-tip electrode on renal VX2 tumors implanted in rabbits. Thirty-three rabbits with implanted renal VX2 tumors were divided into two groups: an RF ablation (RFA) group (n=27) and a control group (n=6). In the RFA group, RFA was performed on 27 implanted VX2 tumors using a cooled RF electrode and they were divided into three subgroups according to the follow-up period: acute (1–3 days, n=12); subacute (1–4 weeks, n=9); and chronic (2–7 months, n=6). Contrast-enhanced spiral CT was performed before the RFA and at the day, day 3, weeks 1, 2, 4, and months 2 and 7, after the RFA. The therapeutic efficacy was evaluated by the survival rate, CT, and pathologic findings. The RFA of renal tumors was technically successful in each instance. Complete tumor ablation was achieved in 22 of the 27 rabbits (81.5%) in the RFA group: 5 rabbits survived longer than 8 weeks without any evidence of viable tumor (18.5%) and 17 rabbits were found free of viable tumors when killed (63.0%). Five rabbits showed local tumor relapse and/or hematogenous lung metastasis after ablation (a recurrence rate of 18.5%). There were 11 (40.7%) complications related to the procedure. This experimental study demonstrates the feasibility of RFA therapy to treat renal VX2 tumors in rabbits, although RFA for central tumors carries some major potential complications, including renal arterial injury. Electronic Publication     

Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes

PURPOSE: To report the safety, technical success, and effectiveness of percutaneous radiofrequency (RF) ablation for renal tumors. MATERIALS AND METHODS: The authors retrospectively reviewed the medical records and imaging studies of 29 consecutive patients (18 men, 11 women; mean age, 65 +/- 2.62 years) with 30 renal tumors (mean diameter, 3.5 +/- 0.24 cm) who underwent percutaneous RF ablation at their institution from September 2001 to March 2004. All procedures were performed with computed tomography guidance with general anesthesia, and all patients were admitted to the hospital for overnight observation. Technical success, complications, and their management were recorded. Technique effectiveness was assessed by imaging and clinical follow up. RESULTS: Overall, 88 overlapping ablations were performed (mean, 2.6 +/- 0.16 ablations per tumor per session) in 34 sessions. There were four major complications (12%). Three patients had gross hematuria and urinary obstruction, all were successfully treated. One patient had persistent anterior abdominal wall weakness. There were also two minor complications (6%) without significant clinical sequelae. One patient had gross hematuria which resolved spontaneously, another patient had transient paresthesia of the anterior abdominal wall. There were no significant changes in renal function after RF ablation. The intent of RF ablation was eradication of the primary tumor in 27 patients and treatment of gross hematuria in the other two. Technical success was achieved in all cases. Follow-up images were available for 26 patients. The primary tumor was completely ablated in 23 of 24 patients (96%) in whom eradication of the primary tumor was attempted (follow up period: mean, 10 months, median 7 months). The two patients treated for hematuria remained asymptomatic for 6 and 27 months each. CONCLUSION: Percutaneous RF ablation for renal tumors is safe and well tolerated. High technical success rates are expected. Early reports of the technique's effectiveness are promising.     

Image-Guided Percutaneous Radiofrequency Ablation of Central Renal Cell Carcinoma: Assessment of Clinical Efficacy and Safety in 31 Tumors

Purpose

To assess clinical efficacy and safety of image-guided percutaneous radiofrequency (RF) ablation of central renal cell carcinoma with adjunctive pyeloperfusion.

Magnetic resonance-guided percutaneous radiofrequency ablation of renal cell carcinomas: a pilot clinical study

OBJECTIVE: The objective of this study was to assess the feasibility and efficacy of magnetic resonance imaging-(MRI) guided percutaneous radiofrequency (RF) ablation of renal cell carcinomas (RCC). SUBJECTS AND METHODS: Twelve patients with RCC (63 to 82 years old) were treated with RF ablation in an interventional 0.2-Tesla open MR unit. Tumor sizes varied from 1.6 cm to 3.9 cm in maximum diameter (tumor volumes 1.9 cm3 to 28.7 cm3). RF procedures were entirely performed in the MR suite. For positioning of the MR-compatible RF-electrode, near real-time MR fluoroscopy by means of rapid gradient echo sequences (acquisition time approximately 2 seconds) was used. Monitoring of ablation was obtained by intermittent imaging with T1- and T2-weighted spin echo sequences. RESULTS: Accurate placement of the RF electrodes was possible in all cases using near real-time MR fluoroscopy. Eleven of 12 patients were successfully treated within 1 single session; 1 patient had to be retreated for tumor relapse at 13 months follow up. Mean number of electrode repositionings under MR guidance during 1 session was 1.7; ablation time ranged between 12 and 28 minutes. Mean duration of 1 treatment session was 5 hours. Coagulation volumes ranged from 7.3 cm3 up to 30.2 cm3. All patients now appear to be disease-free with a mean follow up of 10.3 months (range, 3-23 months). CONCLUSION: MRI-guided RF ablation of RCC in an interventional MR unit is safe and feasible. Fast MR imaging is a convenient method for rapid positioning of MR-compatible RF electrodes. MR monitoring of ablation procedure with T2-weighted imaging allows for immediate assessment of coagulation extent.     

Imaging-guided radiofrequency ablation of solid renal tumors

OBJECTIVE: We performed a retrospective review of imaging-guided radiofrequency ablation of solid renal tumors. MATERIALS AND METHODS: Since May 2000, 35 tumors in 20 patients have been treated with radiofrequency ablation. The size range of treated tumors was 0.9-3.6 cm (mean, 1.7 cm). Reasons for patient referrals were a prior partial or total nephrectomy (nine patients), a comorbidity excluding nephrectomy or partial nephrectomy (10 patients), or a treatment alterative to nephron-sparing surgery (one patient who refused surgery). Tumors were classified as exophytic, intraparenchymal, or central. Sixteen patients had 31 lesions that showed serial growth on CT or MR imaging. Of these 16 patients, four patients with 10 lesions had a history of renal cell carcinoma, and two patients with 11 lesions had a history of von Hippel-Lindau disease. Four patients had incidental solid masses, two of which were biopsied and shown to represent renal cell carcinoma, and the remaining two masses were presumed malignant on the basis of imaging features. Successful ablation was regarded as any lesion showing less than 10 H of contrast enhancement on CT or no qualitative evidence of enhancement after IV gadolinium contrast-enhanced MR imaging. RESULTS: Of the 35 tumors, 22 were exophytic and 13 were intraparenchymal. Twenty-seven of the 35 were treated percutaneously using either sonography (n = 22) or CT (n = 5). Two patients had eight tumors treated intraoperatively using sonography. Patients were followed up with contrast-enhanced CT (n = 18), MR imaging (n = 5), or both (n = 5) with a follow-up range of 1-23 months (mean, 9 months). No residual or recurrent tumor and no major side effects were seen. CONCLUSION: Preliminary results with radiofrequency ablation of exophytic and intraparenchymal renal tumors are promising. Radiofrequency ablation is not associated with significant side effects. Further follow-up is necessary to determine the long-term efficacy of radiofrequency ablation.     

Percutaneous radiofrequency ablation with a multiple-electrode switching-generator system

PURPOSE: To determine the feasibility and safety of treating 35 hepatic tumors with a multiple-electrode switching-generator radiofrequency (RF) ablation system. MATERIALS AND METHODS: The authors performed a retrospective review of percutaneous RF ablation procedures in 35 hepatic tumors ranging in diameter from 0.9 to 3.8 cm and involving 22 patients. Tumors smaller than 2 cm were ablated with a single electrode, and larger tumors were ablated with two or three electrodes depending on tumor size and location of initial electrode placement. Electrodes were positioned 1-2 cm apart to create an intratumoral configuration that maximized index tumor coverage. Computed tomography or magnetic resonance imaging was performed within 24 hours of ablation. The ablation volume, maximum ablation size, and maximum tumor size were compared among the three electrode groups by using analysis of variance. If the global P value with analysis of variance was statistically significant (P<.05), post hoc testing for pairwise comparisons was performed by using the Bonferroni correction to adjust for multiple comparisons. Complications were defined according to the SIR reporting standards for image-guided tumor ablation. RESULTS: Ten tumors were treated with one electrode, 16 were treated with two electrodes, and nine were treated with three electrodes. The mean and median maximum sizes of the tumors ablated with one, two, and three electrodes were 1.2 and 1.1 cm, 2.7 and 2.8 cm, and 3.2 and 3.4 cm, respectively. The mean and median ablation volumes with two electrodes (40.9 and 31.9 cm3, respectively) and three electrodes (59.3 and 48.2 cm3, respectively) were significantly greater than that with one electrode (11.7 and 8.6 cm3, respectively; P相似文献   

Protecting the ureter during radiofrequency ablation of renal cell cancer: a pilot study of retrograde pyeloperfusion with cooled dextrose 5% in water

PURPOSE: To describe early experience with cooled dextrose 5% in water (D5W) solution retrograde pyeloperfusion during radiofrequency (RF) ablation of renal cell carcinoma (RCC) within 1.5 cm of the ureter with respect to feasibility, safety, and incidence of residual/recurrent tumor in proximity to the cooled collecting system. MATERIALS AND METHODS: Between November 2004 and April 2007, 17 patients underwent 19 RF ablation sessions of RCCs within 1.5 cm of the ureter during cooled D5W pyeloperfusion (nine men, eight women; mean tumor size, 3.5 cm; mean age, 73 y; mean distance to ureter, 7 mm). RF ablation was performed with pulsed impedance control current. The records and imaging studies of patients treated with this technique were reviewed for demographics, indication, technique, complications, and tumor recurrence. RESULTS: All 19 RF ablation and ureteral catheter placement procedures were technically successful. No patient developed a ureteral stricture or hydronephrosis during a mean of 14 months of follow-up (range, 4-32 months). Three patients had residual tumor on the first follow-up imaging study, but all three tumors were completely ablated after a second RF ablation session. No complications or deaths occurred. No recurrent tumor was seen anywhere in the treated tumors, and there was complete ablation of the tumor margin in proximity to the collecting system. CONCLUSIONS: RF ablation of RCC within 1.5 cm of the ureter is feasible with cooled D5W retrograde pyeloperfusion and is not associated with reduced efficacy, ureteral injury, or early recurrence.     

Radiofrequency Ablation Combined with Renal Arterial Embolization for the Treatment of Unresectable Renal Cell Carcinoma Larger Than 3.5 cm: Initial Experience

The purpose of the study was to evaluate the feasibility, safety, and therapeutic effects of the combination of renal arterial embolization and radiofrequency (RF) ablation to reinforce the anticancer effect on renal cell carcinomas (RCCs) measuring 3.5 cm or larger. This study was undertaken to evaluate this combined therapy on large RCCs-based tumor geometry. Eleven patients with 12 RCCs 3.5 cm or larger in diameter (3.5–9.0 cm) underwent combined therapy. Two were exophytic tumors, and the remaining 10 tumors had components extending into the renal sinus fat. Tumor vessels were selectively embolized in nine patients and the renal artery was completely embolized in two patients with polyvinyl alcohol or ethanol mixed with iodized oil. RF ablation was percutaneously done under the computed tomographic (CT)–fluoroscopic guidance. Response to treatment was evaluated by dynamic contrast-enhanced CT and magnetic resonance (MR) imaging. Tumor enhancement was eliminated after a single RF session in nine tumors (75%), after two sessions in two tumors (17%), and after four sessions in one tumor (8%). Both exophytic tumors (100%) and 7 of 10 tumors having components in the renal sinus fat (70%) were completely ablated with a single RF session. All tumors remained controlled during a mean follow-up period of 13 months and showed significant reduction in tumor sizes (5.2 ± 1.7 cm to 3.6 ± 1.4 cm, p < 0.001). A delayed abscess developed in the ablated lesion in a patient, which was percutaneously drainaged. Combined therapy as described in this report is a feasible, relatively safe, and promising treatment method for large RCCs regardless of tumor geometry.